Skip to content
Menu

Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $3

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.

Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.

Read at benzinga.com